OVERALL SURVIVAL (OS) RESULTS OF A RANDOMIZED PHASE 2 TRIAL OF PF299804 VERSUS ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AFTER FAILURE OF CHEMOTHERAPY

被引：0
|
作者：
Boyer, Michael [1 ]
Blackhall, Fiona H. [2 ]
Barrios, Carlos H.
Frank, Richard C. [3 ]
Heo, Deo Seog [4 ]
Park, Keunchil [5 ]
Rosell, Rafael [6 ]
Talbot, Denis C. [7 ]
Taylor, Ian C.
Liang, Jane
Campbell, Alicyn K.
O'Connell, Joseph
Ramalingam, Suresh [8 ]
机构：
[1] Sydney Canc Ctr, Sydney, NSW, Australia
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] Norwalk Hosp, Norwalk, CT USA
[4] Seoul Natl Univ Hosp, Seoul, South Korea
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hem Onc,Dept Med, Seoul, South Korea
[6] Catalan Inst Oncol, Girona, Catalonia, Spain
[7] Oxford Oncol Ctr, Oxford, England
[8] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
PF-00299804; Overall survival; Non-small cell lung cancer; EGFR TKI;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S318 / S319
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT)
    Boyer, M. J.
    Blackhall, F. H.
    Park, K.
    Barrios, C. H.
    Krzakowski, M. J.
    Taylor, I.
    Liang, J. Q.
    Denis, L. J.
    O'Connell, J. P.
    Ramalingam, S. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [2] RANDOMIZED PHASE 2 STUDY OF PF299804, AN IRREVERSIBLE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR, VERSUS (V) ERLOTINIB (E) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AFTER CHEMOTHERAPY (CT) FAILURE: QUANTITATIVE AND QUALITATIVE BENEFITS
    Ramalingam, S. S.
    Boyer, M. J.
    Park, K.
    Barrios, C.
    Krzakowski, M.
    Taylor, I.
    Liang, J. Q.
    O'Connell, J. P.
    Campbell, A. K.
    Blackhall, F.
    ANNALS OF ONCOLOGY, 2010, 21 : 122 - 123
  • [3] A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)
    Stinchcombe, T. E.
    Janne, P. A.
    Wang, X.
    Bertino, E. M.
    Weiss, J. M.
    Bazhenova, L.
    Gu, L.
    Lau, C. J.
    Paweletz, C. P.
    Jaslowski, A. J.
    Gerstner, G. J.
    Baggstrom, M. Q.
    Graziano, S. L.
    Beardenlii, J.
    Vokes, E. E.
    ANNALS OF ONCOLOGY, 2018, 29 : 522 - 522
  • [4] Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST)
    Natale, R. B.
    Thongprasert, S.
    Greco, F. A.
    Thomas, M.
    Tsai, C. M.
    Sunpaweravong, P.
    Ferry, D.
    Langmuir, P.
    Rowbottom, J. A.
    Goss, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Updated overall survival (OS) results of randomized phase III trial of erlotiniti (E) versus (v) docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC): Docetaxel and Erlotinib Lung Cancer Trial (DELTA)
    Ibata, Hidenori
    Ando, Masahiko
    Asami, Kazuhiro
    Okano, Yoshio
    Fukuda, Masaaki
    Nakagawa, Hideyuki
    Kozuki, Toshiyuki
    Endo, Tateo
    Tamura, Atsuhisa
    Kamimura, Mitsuhiro
    Sakamoto, Kazuhiro
    Yoshimi, Michihiro
    Soejima, Yoshifumi
    Tomizawa, Yoshio
    Isa, Shun-ichi
    Takada, Minoru
    Saka, Hideo
    Kubo, Akihito
    Kawaguchi, Tomoya
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial
    Rosell, R.
    Gervais, R.
    Vergnenegre, A.
    Massuti, B.
    Felip, E.
    Cardenal, F.
    Garcia Gomez, R.
    Pallares, C.
    Sanchez, J. M.
    Porta, R.
    Cobo, M.
    Di Seri, M.
    Garrido Lopez, P.
    Insa, A.
    De Marinis, F.
    Corre, R.
    Carreras, M.
    Carcereny, E.
    Taron, M.
    Paz-Ares, L. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Progression-free survival (PFS) and overall survival (OS) in phase HI trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC).
    Hotta, K.
    Kiura, K.
    Takigawa, N.
    Tabata, M.
    Fujiwara, Y.
    Tanimoto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Phase I trial of vorinostat in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations after erlotinib progression
    Reguart, N.
    Cardona, A. F.
    Isla, D.
    Cardenal, F.
    Palmero, R.
    Carrasco-Chaumel, E.
    Rolfo, C.
    Massuti, B.
    Moran, T.
    Rosell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Overall Survival (OS) of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) After Negative Invasive Mediastinal Staging
    Bourdages-Pageau, E.
    Vieira, A.
    Labbe, C.
    Figueroa, P. Ugalde
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2233 - S2234
  • [10] Phase II trial of erlotinib maintenance therapy after platinun-based chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Cobo, M.
    Martinez, J.
    Montesa, A.
    Gil-Calle, S.
    Villar-Chamorro, E.
    Ales, I.
    Gutierrez, V.
    Duran, G.
    Carabantes-Ocon, F.
    Benavides, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345